Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.61 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | GRK6 | P43250 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CLK3 | P49761 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152896 | 0.87 | NR1H2 (0.60) | NR1H2NR1H3DCUN1D1ADORA2AADORA1 | |
| SCHEMBL6448731 | 0.84 | NR1H2 (0.56) | NR1H2NR1H3DCUN1D1ADORA2AADORA1 | |
| SCHEMBL6451501 | 0.82 | SMN1; SMN2 (0.57) | NR1H2NR1H3DCUN1D1GAA | |
| SCHEMBL6456324 | 0.81 | GAA (0.50) | NR1H2NR1H3GRK6CYP19A1GAA | |
| SCHEMBL17279794 | 0.80 | NR1H2 (0.86) | NR1H2NR1H3DCUN1D1ADORA2AADORA1 | |
| SCHEMBL6448919 | 0.80 | GRK6 (0.47) | NR1H2NR1H3ADORA2AADORA1AURKA | |
| SCHEMBL6454610 | 0.80 | GAA (0.51) | NR1H2NR1H3GRK6CYP19A1GAA | |
| SCHEMBL6450315 | 0.80 | NR1H2 (0.67) | NR1H2NR1H3DCUN1D1ADORA2AADORA1 | |
| SCHEMBL10094648 | 0.80 | DYRK1A (0.62) | ADORA2AAURKADYRK1ACLK4CYP19A1 | |
| SCHEMBL6449961 | 0.79 | NPC1 (0.66) | DYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NR1H2 34/4885NR1H3 24/4885DCUN1D1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.